Biomarkers for Left Ventricular Reverse Remodeling in Heart Failure (REVERT-HF)

Prior treatment

• Myocardial infarction (defined by elevated cardiac enzymes with ischemic symptoms or new ischemic ECG changes), unstable angina, stroke, or transient ischemic attack (TIA) within 90 days prior to enrollment.
• Coronary revascularization (PCI/CABG) or valve repair/replacement within 1 month prior to enrollment, or planned to undergo such procedures after enrollment.
• CRT implantation within 1 month prior to enrollment, or planned CRT implantation during the study period.
• Prior heart transplantation or ventricular assist device (VAD) implantation, or planned VAD implantation during the study period.
• Alternative or concomitant diagnoses that could explain the participant's heart failure symptoms and signs (e.g., severe anemia, hypothyroidism, nephrotic syndrome).
• Primary pulmonary hypertension, chronic pulmonary embolism, or severe pulmonary disease (including COPD requiring home oxygen or frequent hospitalizations, or COPD exacerbation requiring invasive mechanical ventilation within 12 months prior to enrollment).
• Major surgery (as judged by the investigator) within 90 days prior to enrollment, or planned major elective surgery within 90 days after screening.
• Paroxysmal or permanent atrial fibrillation excluded only if:
  • Requiring cardioversion (e.g., electrical cardioversion, atrial fibrillation ablation, or antiarrhythmic therapy) within ≤ 3 months prior to screening.
  • Heart rate not adequately controlled with anticoagulation therapy for at least 3 months prior to screening.
• Participation in another clinical trial and use of an investigational drug within 1 month prior to enrollment.

Other illness

• Poor treatment adherence that may lead to worsening heart failure symptoms and signs due to non-compliance with prescribed medication.
• History of specific cardiomyopathies, including restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic obstructive cardiomyopathy, infiltrative cardiomyopathy (including but not limited to amyloidosis), familial or genetic cardiomyopathy, or arrhythmogenic right ventricular cardiomyopathy.
• Complex congenital heart disease or severe uncorrected primary valvular heart disease.
• Life expectancy \< 1 year due to non-cardiovascular causes (including but not limited to malignant tumors).
• Active malignancy or history of malignancy diagnosed within 2 years prior to screening, except for: (a) adequately treated basal cell carcinoma of the skin; (b) carcinoma in situ of the cervix; (c) low-risk prostate cancer (defined as PSA \< 10 ng/mL, Gleason score ≤ 6, and clinical stage T1c or T2a prior to treatment).
• Known blood-borne infectious diseases.
• Any other clinically significant disease, malignancy, active infection, condition, or disorder that, in the opinion of the investigator or medical monitor, may pose a safety risk to the participant or interfere with the evaluation, procedures, or completion of the study.

Lab values

• Hepatic impairment: total bilirubin ≥ 1.5 × upper limit of normal (ULN), or ALT/AST ≥ 3 × ULN (patients with Gilbert's syndrome and unconjugated hyperbilirubinemia with total bilirubin ≥ 1.5 × ULN but without other evidence of hepatic impairment may be enrolled).
• Severe or unstable kidney disease: eGFR \< 20 mL/min/1.73 m² (CKD-EPI) at randomization, rapidly deteriorating renal function, or requiring renal replacement therapy.
• Hemoglobin level \< 9 g/dL.

Other

• Systolic blood pressure \< 90 mmHg at enrollment or symptomatic hypotension within the past 24 hours.
• Symptomatic bradycardia or second/third-degree atrioventricular block without a pacemaker.
• Systolic blood pressure ≥ 160 mmHg (if on \< 3 antihypertensive agents) or ≥ 180 mmHg (regardless of treatment) at enrollment.

• Age ≥ 18 and ≤ 90 years at the time of signing informed consent.
• Diagnosed with symptomatic chronic heart failure with reduced ejection fraction (NYHA class II-IV) and has been on stable, optimized guideline-directed medical therapy and/or device therapy for at least 4 weeks.
• Left ventricular ejection fraction ≤ 40% assessed by echocardiography or cardiac MRI within 1 month prior to enrollment.
  • For patients who have undergone coronary revascularization (PCI or CABG), valve repair/replacement, cardiac resynchronization therapy (CRT), or other treatments that may improve LVEF (e.g., initiation of beta-blockers), LVEF must be reassessed at least 1 month after the intervention before enrollment.
  • If multiple LVEF measurements are available, the most recent one will be used for eligibility determination.
• NT-proBNP level measured at enrollment meeting at least one of the following criteria:
  • For LVEF 36%-40%: NT-proBNP ≥ 2500 pg/mL (sinus rhythm) or ≥ 5000 pg/mL (atrial fibrillation).
  • For LVEF 31%-35%: NT-proBNP ≥ 1000 pg/mL (sinus rhythm) or ≥ 2000 pg/mL (atrial fibrillation).
  • For LVEF ≤ 30%: NT-proBNP ≥ 600 pg/mL (sinus rhythm) or ≥ 1200 pg/mL (atrial fibrillation).
  • For patients rehospitalized for heart failure (LVEF ≤ 40% with heart failure hospitalization within the past 12 months): NT-proBNP ≥ 600 pg/mL (sinus rhythm) or ≥ 1200 pg/mL (atrial fibrillation).
• Receiving standard HFrEF medical therapy, unless contraindicated or intolerant, and stable for at least 4 weeks (excluding diuretic dose adjustments). The regimen should include, if applicable: ACE inhibitor, ARB, or sacubitril/valsartan (ARNI) + beta-blocker + mineralocorticoid receptor antagonist (MRA) + SGLT2 inhibitor. Other agents such as vericiguat may be used with documentation.
• Estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m² (CKD-EPI) at enrollment.
• Willing and able to provide signed informed consent and comply with the requirements of the protocol.